Article
The incidence rate of joint surgery among patients with psoriatic arthritis (PsA) has remained persistently high, double that of the general population, according to a new Danish cohort study.
All News
Article
Part II of this series is a direct message to rheumatologists. If we’re doing such a great job in RA, then why do we need a war on RA? Why is this conflict being laid at the feet of good soldier rheumatologists, those who toil daily at winning therapeutic battles one patient at a time? The reasons are blunt and true.
Article
A 12‐month, Phase 2 trial has shown that subcutaneous abatacept was well tolerated in patients with diffuse cutaneous systemic sclerosis (dcSSc), but failed to significantly change the skin outcomes as measured by the change in modified Rodnan skin score (mRSS)
Dr. John Cush
Tweet
A prospective 10-year study of 1,024 older women shows that severe abdominal aortic calcification (AAC) scores were associated with ncreased fracture risk (HR 1.48 [1.15-1.91], p=0.002; not fully indicated by predictors of bone structure. https://t.co/NVbo9eHcYF
Dr. John Cush
Tweet
Observational study of 124 gouty patients with high cholesterol & triglycerides treated with ULT (febuxostat, allopurinol, benzbromarone) showed that ULT significantly lowered SUA and lipid levels too. https://t.co/JSdh3TRTX3
Dr. John Cush
Tweet
NHANES analysis shows that higher serum uric acid (SUA) levels had a greater risk of coronary heart disease and stroke mortality (mainly women >50 years); but there was no link between SUA and all-cause and cancer mortality. https://t.co/UGNSiKsjQl
Dr. John Cush
Tweet
The War on RA - is being fought daily by rheumatologists - Change, Innovation and Discovery will be driven by Rheumatologists if we are to win this war. This is the 2nd of a series on the immense challenge of #RA today. We need you! https://t.co/7vOzRvvuVi
Dr. John Cush
Tweet
Cohort study shows ACE inhib. in Systemic Sclerosis at Dx was assoc w/ increased risk for Scleroderma Renal Crisis (SRC). Military System EHR study of 31 SRC to 332 non-SRC & found ACEi assoc w/ SRC (OR 4.1; CI 1.6–10.2) only in presence of proteinuria https://t.co/cMsheXrmRY
Dr. John Cush
Tweet
Is tea consumption associated with a risk of fractures? A metanalysis of 16 studies, 772,707 participants, high (compared to low) tea consumption was associated a lower fracture risk - RR 0.86 (0.78–0.94). https://t.co/24XYyUArS9
Dr. John Cush
Tweet
Billion dollar companies (J&J, Pfizer) legally sparing over Billion dollar drugs! FTC is investigating Remicade contracting practices. Pfizer (for Inflectra) asserts J&J violated antitrust laws, anticompetitive practices aimed to block Inflectra sales https://t.co/3yk4AcM5ZW
Dr. John Cush
Tweet
FDA will review to Genentechs application for Rituxan use in pediatric (age >2yrs) granulomatosis with polyangiitis & microscopic polyangiitis. If approved, this would be the 1st pediatric indication for RTX; data based on ths phase IIa PePRS study https://t.co/rRFiyQNKca
Dr. John Cush
Tweet
Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
Dr. John Cush
Tweet
Testosterone replacement therapy Increases the risk of CV events (MI/CVA/TIA). Study of 15,401 men, >45 yrs old, w/ low testosterone & no evidence of hypogonadotropic or testicular dz (1995-2017). HR 1.21; CI 1.0-1.46), highest in the 1st 2yrs https://t.co/nNXyFIo1EH
Dr. John Cush
Tweet
Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has adopted a negative opinion on Application for romosozumab (Evenity) for the treatment of severe osteoporosis (by Amgen & UCB); an appeal is planned https://t.co/EVjxuBQdF0
Dr. John Cush
Tweet
Im starting a War on RA. I need you go get mad and do your part. Read 1st of 4 part series https://t.co/sR5Z3lq8CU or watch it here https://t.co/s7CVW2dNUT
Dr. John Cush
Tweet
The FDA Arthritis Advisory Committee voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
Dr. John Cush
Tweet
The RheumNow Podcast is up! News, Announcements of generics/biosimilars, approvals and FDA hearings. Watch the video here>> https://t.co/3tW7uRivgQ or listen to the podcast on iTunes>> https://t.co/q2bscJkIhs
NEJM
Tweet
Image challenge: A 48-year-old man presented to the dermatology clinic with a 6-month history of painful hand ulcerations and shortness of breath. He has no muscle weakness or arthritis. What is the diagnosis? https://t.co/kQrNuVExlQ https://t.co/n3435OCPLA
Dr. John Cush
Tweet
The FDA Arthritis Advisory Committee has voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
Peter Nash
Tweet
Effect of Filgotinib in Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drugs - JAMA July 23/30 - Filgo (Jak1 inhib) efficacy in Bdmard-IR - selling point for Filgo = less Zoster, 300 pts for 6 mths 1.4% zoster in this study so watch this space
